Definitive Healthcare (DH)
Market Price (4/19/2026): $1.07 | Market Cap: $110.6 MilSector: Health Care | Industry: Health Care Technology
Definitive Healthcare (DH)
Market Price (4/19/2026): $1.07Market Cap: $110.6 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -75% Attractive yieldFCF Yield is 35% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Cloud Computing. Themes include Health Data Analytics, AI in Healthcare Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -125%, 3Y Excs Rtn is -165% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.5% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.2%, Rev Chg QQuarterly Revenue Change % is -1.2% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -134% Key risksDH key risks include [1] a structural revenue decline and weak client retention leading to market share loss, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -75% |
| Attractive yieldFCF Yield is 35% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Cloud Computing. Themes include Health Data Analytics, AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -125%, 3Y Excs Rtn is -165% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.5% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.2%, Rev Chg QQuarterly Revenue Change % is -1.2% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -134% |
| Key risksDH key risks include [1] a structural revenue decline and weak client retention leading to market share loss, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Definitive Healthcare (DH) stock has lost about 65% since 12/31/2025 because of the following key factors:
1. Definitive Healthcare reported a significant earnings miss in Q4 2025 and issued weak guidance for 2026.
The company announced a basic earnings per share (EPS) loss of -$0.09 for Q4 2025, substantially missing analysts' anticipated $0.06. This period also included $19.5 million in goodwill impairment charges, contributing to a full-year 2025 net loss of $199.3 million, inclusive of $196.1 million in goodwill impairment charges. Furthermore, Definitive Healthcare initiated its 2026 revenue guidance 5% below consensus estimates and adjusted EBITDA guidance 15% below consensus. The company also experienced a decline in its customer base, with total customers decreasing from 2,400 in Q3 2025 to 2,330 in Q4 2025, and enterprise customers falling from 520 to 511 during the same period.
2. Analysts consistently downgraded Definitive Healthcare's stock and lowered price targets.
Following the Q4 2025 results and weak 2026 outlook, several analysts reduced their price targets for DH. BofA Securities, for instance, lowered its price target to $3.50 from $4.00 on April 10, 2026, citing the lower 2026 outlook and compression in peer multiples. Barclays also cut its price target to $1.00 from $2.75 while maintaining an "Underweight" rating. Additionally, Stephens adjusted its price target for the company from $3.00 to $2.00 due to ongoing revenue declines. The consensus among Wall Street analysts has shifted to a "Reduce" or "Hold" rating for DH shares.
Show more
1. Definitive Healthcare reported a significant earnings miss in Q4 2025 and issued weak guidance for 2026.
The company announced a basic earnings per share (EPS) loss of -$0.09 for Q4 2025, substantially missing analysts' anticipated $0.06. This period also included $19.5 million in goodwill impairment charges, contributing to a full-year 2025 net loss of $199.3 million, inclusive of $196.1 million in goodwill impairment charges. Furthermore, Definitive Healthcare initiated its 2026 revenue guidance 5% below consensus estimates and adjusted EBITDA guidance 15% below consensus. The company also experienced a decline in its customer base, with total customers decreasing from 2,400 in Q3 2025 to 2,330 in Q4 2025, and enterprise customers falling from 520 to 511 during the same period.
2. Analysts consistently downgraded Definitive Healthcare's stock and lowered price targets.
Following the Q4 2025 results and weak 2026 outlook, several analysts reduced their price targets for DH. BofA Securities, for instance, lowered its price target to $3.50 from $4.00 on April 10, 2026, citing the lower 2026 outlook and compression in peer multiples. Barclays also cut its price target to $1.00 from $2.75 while maintaining an "Underweight" rating. Additionally, Stephens adjusted its price target for the company from $3.00 to $2.00 due to ongoing revenue declines. The consensus among Wall Street analysts has shifted to a "Reduce" or "Hold" rating for DH shares.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -64.1% change in DH stock from 12/31/2025 to 4/18/2026 was primarily driven by a -64.2% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.87 | 1.03 | -64.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 242 | 242 | -0.3% |
| P/S Multiple | 1.2 | 0.4 | -64.2% |
| Shares Outstanding (Mil) | 104 | 103 | 0.4% |
| Cumulative Contribution | -64.1% |
Market Drivers
12/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| DH | -64.1% | |
| Market (SPY) | -5.4% | 26.8% |
| Sector (XLV) | -3.9% | 8.1% |
Fundamental Drivers
The -74.6% change in DH stock from 9/30/2025 to 4/18/2026 was primarily driven by a -75.1% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.06 | 1.03 | -74.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 245 | 242 | -1.4% |
| P/S Multiple | 1.8 | 0.4 | -75.1% |
| Shares Outstanding (Mil) | 107 | 103 | 3.4% |
| Cumulative Contribution | -74.6% |
Market Drivers
9/30/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| DH | -74.6% | |
| Market (SPY) | -2.9% | 28.4% |
| Sector (XLV) | 7.4% | 8.7% |
Fundamental Drivers
The -64.4% change in DH stock from 3/31/2025 to 4/18/2026 was primarily driven by a -66.6% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.89 | 1.03 | -64.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 252 | 242 | -4.2% |
| P/S Multiple | 1.3 | 0.4 | -66.6% |
| Shares Outstanding (Mil) | 115 | 103 | 11.3% |
| Cumulative Contribution | -64.4% |
Market Drivers
3/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| DH | -64.4% | |
| Market (SPY) | 16.3% | 25.3% |
| Sector (XLV) | 3.3% | 14.4% |
Fundamental Drivers
The -90.0% change in DH stock from 3/31/2023 to 4/18/2026 was primarily driven by a -91.0% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.33 | 1.03 | -90.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 223 | 242 | 8.5% |
| P/S Multiple | 4.9 | 0.4 | -91.0% |
| Shares Outstanding (Mil) | 105 | 103 | 1.7% |
| Cumulative Contribution | -90.0% |
Market Drivers
3/31/2023 to 4/18/2026| Return | Correlation | |
|---|---|---|
| DH | -90.0% | |
| Market (SPY) | 63.3% | 27.0% |
| Sector (XLV) | 20.3% | 17.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DH Return | -37% | -60% | -10% | -59% | -30% | -63% | -98% |
| Peers Return | 11% | -37% | -2% | -15% | -23% | -27% | -67% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 87% |
Monthly Win Rates [3] | |||||||
| DH Win Rate | 0% | 42% | 50% | 33% | 58% | 0% | |
| Peers Win Rate | 58% | 35% | 45% | 43% | 37% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DH Max Drawdown | -41% | -63% | -48% | -64% | -45% | -67% | |
| Peers Max Drawdown | -13% | -50% | -25% | -32% | -37% | -34% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IQV, VEEV, HCAT, MDRX, CERT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)
How Low Can It Go
| Event | DH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -88.4% | -25.4% |
| % Gain to Breakeven | 759.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to IQV, VEEV, HCAT, MDRX, CERT
In The Past
Definitive Healthcare's stock fell -88.4% during the 2022 Inflation Shock from a high on 9/17/2021. A -88.4% loss requires a 759.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Definitive Healthcare (DH)
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. cwas founded in 2011 and is headquartered in Framingham, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Definitive Healthcare (DH):
Bloomberg for the healthcare industry
ZoomInfo for healthcare businesses
AI Analysis | Feedback
- Healthcare Commercial Intelligence Platform: A comprehensive platform that delivers data and insights on healthcare providers and their activities.
- Sales & Marketing Intelligence Modules: Services providing targeted data and insights to optimize sales and marketing strategies for healthcare customers.
- Product Development & Clinical Research Intelligence Modules: Services offering essential information to support the development of healthcare products and clinical research efforts.
- Strategy Intelligence Modules: Services delivering data-driven insights to aid in strategic planning and decision-making within the healthcare industry.
- Talent Acquisition Intelligence Modules: Services providing information and analytics to assist healthcare organizations in identifying and acquiring talent.
- Physician Network Management Intelligence Modules: Services offering data and insights crucial for the effective planning and management of physician networks.
AI Analysis | Feedback
Definitive Healthcare (symbol: DH) primarily sells its healthcare commercial intelligence solutions to other companies rather than to individuals. Based on the provided information, specific names of major customer companies are not disclosed, which is typical for B2B companies serving a broad range of clients. However, the company's description identifies the following major categories of customers that utilize its services:
- Biopharmaceutical and Medical Device Companies: These organizations use Definitive Healthcare's platform for various functions, including product development, go-to-market planning, and sales and marketing execution.
- Healthcare Information Technology (IT) Companies: Businesses in the healthcare IT sector leverage the intelligence provided for strategic and operational insights.
- Healthcare Providers: This category includes hospitals, health systems, and other entities that deliver healthcare services, utilizing the data for purposes like physician network management and strategic planning.
- Other Diversified Companies in the Healthcare Ecosystem: This broad category includes a variety of other organizations that have a stake in the healthcare industry, such as:
- Staffing companies
- Commercial real estate companies
- Financial institutions
- Other organizations that interact with or serve the healthcare sector.
Since the company's public description does not list specific names of its major customer companies, their corresponding public symbols cannot be provided.
AI Analysis | Feedback
Amazon.com, Inc. (AMZN)
AI Analysis | Feedback
Kevin Coop, Chief Executive Officer Kevin Coop joined Definitive Healthcare as CEO and a member of the Board of Directors in June 2024. Prior to this, he was the CEO and a board member at DailyPay, Inc., a financial services work technology company. His career, spanning over 30 years, includes numerous executive leadership roles focused on the growth of data and analytics assets. He also served as President of North America at Dun & Bradstreet and President of Data Analytics at Black Knight. Additionally, he was Group President of the financial services businesses of Verisk Analytics, and held CEO roles at OptumInsight, Optum360, and Optum Analytics within Optum, a division of UnitedHealth Group. He was also Chairman and Chief Executive Officer of The Advisory Board Company, which Optum acquired in 2017. Before joining The Advisory Board Company, Mr. Coop was an Associate Principal with McKinsey & Company. Casey Heller, Chief Financial Officer Casey Heller leads Definitive Healthcare's financial strategy and operations as Chief Financial Officer. She previously held the role of Senior Vice President of Finance, beginning in January 2024. Before joining Definitive Healthcare, Ms. Heller spent nearly 15 years at IBM, where she held several leadership roles, including investor relations, treasury strategy, Chief of Staff to the CFO, and overseeing financial planning and analysis (FP&A) for the software business. Jason Krantz, Executive Chairman of the Board and Founder Jason Krantz founded Definitive Healthcare in 2011 and currently serves as Executive Chairman of the Board. He previously served as the company's Chief Executive Officer since its founding until August 2022, and as Interim CEO from January 2024 to June 2024. Before founding Definitive Healthcare, Mr. Krantz founded and was CEO of Infinata, a SaaS-based provider of intelligence to the pharmaceutical industry under the brand BioPharm Insight, which was sold to Pearson Media Group in 2007. He has also co-founded and helped build other intelligence and analytics companies, including Energy Acuity and Xtelligent Media, both of which have been sold. He also served on the board of RainKing Solutions, which was acquired. Definitive Healthcare itself received its first institutional investment from Spectrum Equity. Ben Graboske, Executive Vice President Technology & Engineering, Chief Data Officer Ben Graboske is the Executive Vice President of Technology & Engineering and Chief Data Officer at Definitive Healthcare, where he leads the company's data strategy, product innovation, and engineering initiatives globally. Before Definitive Healthcare, Mr. Graboske was President of Mortgage Data & Analytics at ICE, a global financial services company. His prior experience also includes serving as President of Data & Analytics at Black Knight, Inc., Senior Vice President of Real Estate & Financial Services at CoreLogic, Vice President of Mortgage and Analytics Technology at Interthinx, and Chief Information Officer at Move, Inc. & Realtor.com. Jonathan Paris, Chief Legal Officer and Secretary Jonathan Paris is the Chief Legal Officer and Secretary for Definitive Healthcare. He is a seasoned legal executive and commercial attorney who has advised domestic and multinational publicly traded and privately held organizations. Before joining Definitive Healthcare, Jonathan was the General Counsel & Head of Corporate Strategy at FluidForm Bio. He also served as Senior Vice President, Secretary, and General Counsel of Rapid Micro Biosystems, a life sciences technology company, and held various leadership positions at Insulet Corporation, Medtronic, and Covidien.AI Analysis | Feedback
The public company Definitive Healthcare (symbol: DH) faces several key risks to its business, primarily stemming from intense market competition, evolving regulatory landscapes concerning data privacy and security, and ongoing financial and profitability challenges. Here are the key risks identified:- Intense Market Competition and Revenue Decline: Definitive Healthcare operates in a highly competitive healthcare analytics sector, contending with established players such as IQVIA, S&P Global, Veeva Systems, Clarivate, and Komodo Health. This intense competition has contributed to revenue declines in recent quarters, with a reported 7% year-over-year drop in Q1 2025 and a 6% decrease in subscription revenue in Q2 2025. The competitive pressure also impacts pricing power and market share within the dynamic healthcare commercial intelligence sector. Weak client retention and a lack of near-term turnaround prospects further highlight challenges in this competitive environment.
- Regulatory Changes, Data Privacy, and Cybersecurity Risks: As a provider of healthcare commercial intelligence, Definitive Healthcare handles sensitive patient and provider data, making it highly susceptible to regulatory changes and data security threats. The company faces risks associated with evolving regulations, including HIPAA and GDPR, as well as new federal and state regulations concerning AI in healthcare. Cybersecurity threats, such as ransomware, phishing, and data breaches, are escalating in the healthcare industry, with significant financial and reputational consequences for organizations that fail to protect sensitive information. Mishandling patient data or non-compliance with regulations can lead to substantial fines, legal liabilities, and erosion of client trust.
- Financial Health and Profitability Challenges: Definitive Healthcare has demonstrated ongoing profitability challenges, reporting significant net losses on a trailing twelve-month basis, with quarterly net losses experienced throughout FY 2025. The company's adjusted EBITDA margins have also decreased. While Definitive Healthcare has generated positive cash flow from operations, concerns exist regarding goodwill impairments and equity erosion, raising questions about long-term sustainability. The company's financial strength has been rated as poor due to high debt levels, and its Altman Z-Score indicates a potential risk of bankruptcy. Additionally, challenges with customer retention rates directly impact its subscription-driven business model and revenue growth.
AI Analysis | Feedback
The clear emerging threat for Definitive Healthcare is the rapid advancement and adoption of artificial intelligence (AI), particularly generative AI and large language models (LLMs).
Definitive Healthcare's core business revolves around collecting, processing, and presenting healthcare commercial intelligence. AI and LLMs are becoming increasingly sophisticated at autonomously gathering, synthesizing, and analyzing vast quantities of structured and unstructured data from diverse sources, including public records, news, scientific publications, and financial reports. This technology could enable new competitors to develop highly efficient and cost-effective platforms for generating commercial intelligence, potentially automating significant portions of the data aggregation, analysis, and insight generation processes that Definitive Healthcare currently provides.
Furthermore, LLMs could empower customers to develop their own sophisticated in-house intelligence capabilities by leveraging readily available data and AI tools, potentially reducing their reliance on third-party intelligence providers. This shift could fundamentally disrupt the traditional model of selling access to curated intelligence platforms, similar to how streaming services disrupted physical media rentals or how app-based ride-sharing services disrupted traditional taxi dispatch systems.
AI Analysis | Feedback
Definitive Healthcare's (DH) estimated total addressable market (TAM) for its healthcare commercial intelligence platform is over $10 billion. This market primarily encompasses companies operating within the U.S. healthcare ecosystem that could benefit from Definitive Healthcare's solutions.
More broadly, Definitive Healthcare operates within the global healthcare business intelligence market, which was valued at $10.05 billion in 2024 and is projected to grow to $35.72 billion by 2034, with a compound annual growth rate (CAGR) of 13.52% from 2025 to 2034. Additionally, the global healthcare data and analytics market, a wider sector, was estimated at $30 billion in 2024 and is projected to reach $74 billion by 2031, with a CAGR of 15.2% from 2025 to 2031.
AI Analysis | Feedback
Definitive Healthcare (NASDAQ: DH) is strategically focusing on several key areas to drive future revenue growth over the next two to three years, despite a near-term revenue decline projected for 2026. These drivers are rooted in expanding its offerings, leveraging technological advancements, and deepening customer engagement.
Here are 4 expected drivers of future revenue growth for Definitive Healthcare:
- Expansion of Professional Services and New Data Offerings: Definitive Healthcare saw a substantial 49% year-over-year increase in professional services revenue in the fourth quarter of 2025. This growth is anticipated to continue as the company secures new clients, such as a global leader in integrated therapy solutions, who selected Definitive Healthcare to support U.S. market expansion. This partnership is expected to create opportunities for additional professional services and data sets as the customer introduces new products.
- Product Innovation and AI Integration to Enhance Upsell and Cross-sell: The company plans to integrate generative AI (GenAI) into its flagship Vue platform, with a launch targeted for the next quarter (Q1 2026). This strategic investment aims to increase upsell and cross-sell opportunities with existing customers by enhancing product value. Definitive Healthcare believes that investing in its platform and utilizing both existing and new data sets to launch or improve multiple products is an effective way to deliver greater value to customers.
- Targeted Customer Segment Expansion and Focus on Enterprise Accounts: While the life sciences segment has experienced some upsell and downsell pressure, Definitive Healthcare observed growth in its diversified and provider customer segments in the fourth quarter of 2025. Furthermore, the company improved its gross dollar retention among enterprise accounts, which are a primary focus of its go-to-market strategies and represent a significant portion of its Annual Recurring Revenue (ARR). Continued focus on these growing segments and high-value enterprise clients is expected to contribute to future revenue.
- Enhanced Data Differentiation and Quality: Definitive Healthcare has made significant progress in data differentiation, including the successful remediation and restoration of claims data volumes to above historical levels following industry-wide disruption. The release of new claims data sources bolsters the core value of the company's offerings, which is critical for attracting new customers and retaining existing ones in the competitive healthcare market. This commitment to superior data quality is a key factor in securing new business and maintaining a competitive edge.
AI Analysis | Feedback
Capital Allocation Decisions for Definitive Healthcare (DH)
Share Issuance
- Definitive Healthcare Corp. completed its Initial Public Offering (IPO) on September 17, 2021, marking a significant share issuance event to public investors.
- The proceeds from the IPO were intended to be used to purchase newly issued LLC Units from Definitive OpCo, acquire LLC Units from certain Pre-IPO LLC Members, and repurchase a portion of Class A common stock received by certain equityholders.
- As of February 23, 2026, the company had 104,472,371 shares of Class A common stock outstanding.
Inbound Investments
- Definitive Healthcare raised $4.31 million in funding over three rounds, with its latest Series A funding round occurring on April 6, 2021, with participation from Spectrum Equity and 22C Capital.
Outbound Investments
- On January 16, 2024, Definitive Healthcare completed a merger/acquisition with Carevoyance. This acquisition's effect was included in the company's financial guidance for 2024.
- In 2021, Definitive Healthcare also acquired Analytical Wizards, which was highlighted in its Q4 and full-year fiscal 2021 financial results.
Capital Expenditures
- Capitalized software development spending amounted to $6 million for the full year 2025, representing a $5 million increase from the prior year (2024).
- For the fourth quarter of 2025, Definitive Healthcare invested $4.4 million in capital expenditures.
- The company anticipates lower planned capital expenditure spending in 2026 compared to 2025, which is expected to improve the adjusted EBITDA to unlevered free cash flow conversion.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Definitive Healthcare Earnings Notes | 12/16/2025 | |
| Would You Still Hold Definitive Healthcare Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to DH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.26 |
| Mkt Cap | 0.7 |
| Rev LTM | 503 |
| Op Inc LTM | 1 |
| FCF LTM | 77 |
| FCF 3Y Avg | 53 |
| CFO LTM | 106 |
| CFO 3Y Avg | 69 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.9% |
| Rev Chg 3Y Avg | 4.1% |
| Rev Chg Q | 1.0% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Inc Chg LTM | 13.3% |
| Op Inc Chg 3Y Avg | 30.6% |
| Op Mgn LTM | 0.8% |
| Op Mgn 3Y Avg | 3.3% |
| QoQ Delta Op Mgn LTM | -0.7% |
| CFO/Rev LTM | 21.0% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 14.8% |
| FCF/Rev 3Y Avg | 14.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.7 |
| P/S | 1.3 |
| P/Op Inc | 5.5 |
| P/EBIT | 6.2 |
| P/E | -0.6 |
| P/CFO | 10.8 |
| Total Yield | -9.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.5% |
| D/E | 0.5 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.3% |
| 3M Rtn | -30.2% |
| 6M Rtn | -44.4% |
| 12M Rtn | -39.1% |
| 3Y Rtn | -70.0% |
| 1M Excs Rtn | -11.6% |
| 3M Excs Rtn | -33.4% |
| 6M Excs Rtn | -51.6% |
| 12M Excs Rtn | -71.9% |
| 3Y Excs Rtn | -143.3% |
Price Behavior
Price Behavior
| Market Price | $1.03 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 09/15/2021 | |
| Distance from 52W High | -76.0% | |
| 50 Days | 200 Days | |
| DMA Price | $1.26 | $2.74 |
| DMA Trend | down | down |
| Distance from DMA | -18.5% | -62.4% |
| 3M | 1YR | |
| Volatility | 78.6% | 71.3% |
| Downside Capture | 2.11 | 1.28 |
| Upside Capture | 26.39 | 76.20 |
| Correlation (SPY) | 26.5% | 28.7% |
DH Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.51 | 1.37 | 1.54 | 1.57 | 0.93 | 1.19 |
| Up Beta | 9.94 | 3.22 | 5.00 | 3.57 | 0.71 | 0.75 |
| Down Beta | -3.50 | -1.85 | -0.14 | 0.53 | 0.74 | 1.02 |
| Up Capture | 19% | -15% | -63% | -22% | 52% | 75% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 15 | 24 | 48 | 114 | 347 |
| Down Capture | 154% | 316% | 279% | 218% | 146% | 112% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 11 | 22 | 34 | 71 | 121 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DH | |
|---|---|---|---|---|
| DH | -59.0% | 71.0% | -0.97 | - |
| Sector ETF (XLV) | 9.6% | 16.0% | 0.39 | 12.9% |
| Equity (SPY) | 21.1% | 12.9% | 1.32 | 29.6% |
| Gold (GLD) | 50.9% | 27.5% | 1.49 | -8.1% |
| Commodities (DBC) | 25.2% | 16.2% | 1.40 | -6.2% |
| Real Estate (VNQ) | 17.5% | 13.7% | 0.93 | 24.1% |
| Bitcoin (BTCUSD) | -7.8% | 42.6% | -0.08 | 18.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DH | |
|---|---|---|---|---|
| DH | -52.7% | 67.9% | -0.91 | - |
| Sector ETF (XLV) | 6.4% | 14.6% | 0.25 | 24.5% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 35.1% |
| Gold (GLD) | 22.6% | 17.8% | 1.04 | -0.1% |
| Commodities (DBC) | 11.6% | 18.8% | 0.51 | 3.6% |
| Real Estate (VNQ) | 4.4% | 18.8% | 0.14 | 30.9% |
| Bitcoin (BTCUSD) | 5.2% | 56.5% | 0.31 | 20.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DH | |
|---|---|---|---|---|
| DH | -31.2% | 67.9% | -0.91 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 24.5% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 35.1% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | -0.1% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 3.6% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 30.9% |
| Bitcoin (BTCUSD) | 68.4% | 66.9% | 1.07 | 20.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | -8.6% | -12.9% | -25.0% |
| 11/6/2025 | 10.6% | 2.6% | -10.6% |
| 8/7/2025 | -2.8% | -4.3% | 4.5% |
| 5/8/2025 | 31.3% | 18.1% | 30.2% |
| 2/27/2025 | -34.3% | -46.5% | -40.2% |
| 11/7/2024 | -1.6% | 3.5% | 9.0% |
| 8/5/2024 | 2.8% | 5.1% | 26.8% |
| 5/7/2024 | -26.2% | -24.8% | -21.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 8 | 8 |
| # Negative | 12 | 10 | 10 |
| Median Positive | 11.0% | 6.7% | 15.4% |
| Median Negative | -7.6% | -14.9% | -20.4% |
| Max Positive | 31.3% | 18.1% | 45.2% |
| Max Negative | -34.3% | -46.5% | -40.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | 54.00 Mil | 55.00 Mil | 56.00 Mil | -7.6% | Lower New | Guidance: 59.50 Mil for Q4 2025 | |
| Q1 2026 Adjusted Operating Income | 9.50 Mil | 10.00 Mil | 10.50 Mil | -28.6% | Lower New | Guidance: 14.00 Mil for Q4 2025 | |
| Q1 2026 Adjusted EBITDA | 12.00 Mil | 12.50 Mil | 13.00 Mil | -24.2% | Lower New | Guidance: 16.50 Mil for Q4 2025 | |
| Q1 2026 Adjusted Net Income | 4.00 Mil | 4.50 Mil | 5.00 Mil | -47.1% | Lower New | Guidance: 8.50 Mil for Q4 2025 | |
| 2026 Revenue | 220.00 Mil | 223.00 Mil | 226.00 Mil | -6.9% | Lower New | Guidance: 239.50 Mil for 2025 | |
| 2026 Adjusted Operating Income | 41.50 Mil | 44.00 Mil | 46.50 Mil | -24.1% | Lower New | Guidance: 58.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | 53.00 Mil | 55.50 Mil | 58.00 Mil | -19.0% | Lower New | Guidance: 68.50 Mil for 2025 | |
| 2026 Adjusted Net Income | 21.00 Mil | 23.50 Mil | 26.00 Mil | -31.9% | Lower New | Guidance: 34.50 Mil for 2025 | |
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue | 59.00 Mil | 59.50 Mil | 60.00 Mil | ||||
| Q4 2025 Adjusted Operating Income | 13.50 Mil | 14.00 Mil | 14.50 Mil | ||||
| Q4 2025 Adjusted EBITDA | 16.00 Mil | 16.50 Mil | 17.00 Mil | ||||
| Q4 2025 Adjusted EBITDA Margin | 27.0% | 28.0% | 29.0% | ||||
| Q4 2025 Adjusted Net Income | 8.00 Mil | 8.50 Mil | 9.00 Mil | ||||
| Q4 2025 Adjusted Net Income Per Diluted Share | 0.05 | 0.06 | 0.06 | ||||
| 2025 Revenue | 239.00 Mil | 239.50 Mil | 240.00 Mil | 0.4% | Raised | Guidance: 238.50 Mil for 2025 | |
| 2025 Adjusted Operating Income | 57.50 Mil | 58.00 Mil | 58.50 Mil | 8.4% | Raised | Guidance: 53.50 Mil for 2025 | |
| 2025 Adjusted EBITDA | 68.00 Mil | 68.50 Mil | 69.00 Mil | 4.6% | Raised | Guidance: 65.50 Mil for 2025 | |
| 2025 Adjusted EBITDA Margin | 28.0% | 28.5% | 29.0% | 3.6% | 1.0% | Raised | Guidance: 27.5% for 2025 |
| 2025 Adjusted Net Income | 34.00 Mil | 34.50 Mil | 35.00 Mil | 3.0% | Raised | Guidance: 33.50 Mil for 2025 | |
| 2025 Adjusted Net Income Per Diluted Share | 0.23 | 0.23 | 0.24 | 4.4% | Raised | Guidance: 0.23 for 2025 | |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.